Interaction of mutants of tissue-type plasminogen activator with liver cells: effect of domain deletions.

No abstract is available for this paper.

• Publication year

  1996

• Venue

  Biochemical Journal

• Publication date

  1996-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1042/BJ3130775PMID 8611154PMCID PMC1216977
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• alpha-Fucose-mediated binding and degradation of tissue-type plasminogen activator by HepG2 cells.

  1994cited by this paper
• The role of plasminogen activator inhibitor type 1 in the clearance of tissue-type plasminogen activator by rat hepatoma cells.

  1994cited by this paper
• Low density lipoprotein receptor-related protein is necessary for the internalization of both tissue-type plasminogen activator-inhibitor complexes and free tissue-type plasminogen activator.

  1994cited by this paper
• Cellular receptors for the plasminogen activators.

  1994cited by this paper
• Receptor-mediated endocytosis of tissue-type plasminogen activator by low density lipoprotein receptor-related protein on human hepatoma HepG2 cells.

  1993cited by this paper
• 39-kD protein inhibits tissue-type plasminogen activator clearance in vivo.

  1993cited by this paper
• In vivo and in vitro interaction of high and low molecular weight single-chain urokinase-type plasminogen activator with rat liver cells.

  1992cited by this paper
• Characterization of the interaction both in vitro and in vivo of tissue-type plasminogen activator (t-PA) with rat liver cells. Effects of monoclonal antibodies to t-PA.

  1992cited by this paper
• Low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor is an hepatic receptor for tissue-type plasminogen activator.

  1992cited by this paper
• Thrombolytic properties in a rabbit jugular vein thrombosis model of a tissue-type plasminogen activator mutant lacking the growth factor--and kringle one-domains.

  1992cited by this paper
• Tyrosine 67 in the epidermal growth factor-like domain of tissue-type plasminogen activator is important for clearance by a specific hepatic receptor.

  1992cited by this paper
• Isolation and characterization of the mannose receptor from human liver potentially involved in the plasma clearance of tissue‐type plasminogen activator

  1992cited by this paper
• The receptor for tissue plasminogen activator (t‐PA) in complex with its inhibitor, PAI‐1, on human hepatocytes

  1991cited by this paper
• Different fate in vivo of oxidatively modified low density lipoprotein and acetylated low density lipoprotein in rats. Recognition by various scavenger receptors on Kupffer and endothelial liver cells.

  1991cited by this paper
• Clearance of t-PA, PAI-1, and t-PA-PAI-1 complex in an isolated perfused rat liver system.

  1991cited by this paper
• Endocytosis mediated by the mannose receptor in liver endothelial cells. An immunocytochemical study.

  1990cited by this paper
• Site-directed mutagenesis in human tissue-plasminogen activator. Distinguishing sites in the amino-terminal region required for full fibrinolytic activity and rapid clearance from the circulation.

  1990cited by this paper
• Clearance of Tissue Plasminogen Activator by Mannose and Galactose Receptors in the Liver

  1990cited by this paper
• Identification of determinants involved in binding of tissue-type plasminogen activator-plasminogen activator inhibitor type 1 complexes to HepG2 cells.

  1990cited by this paper
• Tissue plasminogen activator: the biochemistry and pharmacology of variants produced by mutagenesis.

  1990cited by this paper
• Tissue-type plasminogen activator. A review of its pharmacology and therapeutic use as a thrombolytic agent.

  1989cited by this paper
• Thrombolytic therapy in acute myocardial infarction.

  1989cited by this paper
• Catabolism of tissue-type plasminogen activator by the human hepatoma cell line Hep G2. Modulation by plasminogen activator inhibitor type 1.

  1989cited by this paper
• Interactions between tissue-type plasminogen activator and extracellular matrix-associated plasminogen activator inhibitor type 1 in the human hepatoma cell line HepG2.

  1989cited by this paper
• Construction of a tissue plasminogen activator gene having unique restriction sites to facilitate domain manipulation: a model for the analysis of multi-domain proteins.

  1989cited by this paper
• Biochemical determinants of clearance of tissue-type plasminogen activator from the circulation.

  1988cited by this paper
• Tissue Plasminogen Activator is Endocytosed by Mannose and Galactose Receptors of Rat Liver Cells

  1988cited by this paper
• Regulation of tyrosinase synthesis by alpha-melanocyte-stimulating hormone in hair follicular melanocytes of the mouse.

  1988cited by this paper
• Pharmacokinetics and thrombolytic properties of deletion mutants of human tissue-type plasminogen activator in rabbits.

  1988cited by this paper
• Characterization of the interaction in vivo of tissue-type plasminogen activator with liver cells.

  1988cited by this paper
• A tissue-type plasminogen activator mutant with prolonged clearance in vivo. Effect of removal of the growth factor domain.

  1988cited by this paper
• Uptake and Degradation of Tissue Plasminogen Activator in Rat Liver

  1988cited by this paper
• Receptor-mediated endocytosis of tissue-type plasminogen activator by the human hepatoma cell line Hep G2.

  1988cited by this paper
• Structure-function analysis with tissue-type plasminogen activator. Effect of deletion of NH2-terminal domains on its biochemical and biological properties.

  1988cited by this paper
• Advances in biotechnological processes. Volume 6: Edited by Avshalom Mizrahi Alan R. Liss, New York, 1986, 302 pp., £85

  1987cited by this paper
• Isolation and characterization of three different carbohydrate chains from melanoma tissue plasminogen activator.

  1987cited by this paper
• The interaction in vivo of transferrin and asialotransferrin with liver cells.

  1987cited by this paper
• CELLULAR CATABOLISM OF RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR: IDENTIFICATION AND CHARACTERIZATION OF A NOVEL HIGH AFFINITY UPTAKE SYSTEM ON RAT HEPATOCYTES

  1987cited by this paper
• Clearance of the heavy and light polypeptide chains of human tissue-type plasminogen activator in rats.

  1986cited by this paper
• Mechanism of glucagon stimulation of fructose‐1,6‐bisphosphatase in rat hepatocytes

  1986cited by this paper
• Turnover of human tissue plasminogen activator (tPA) in rabbits.

  1986cited by this paper
• Plasminogen activators, tissue degradation, and cancer.

  1985cited by this paper
• Catabolism of human tissue plasminogen activator in mice.

  1985cited by this paper
• Hepatic Clearance of Tissue-Type Plasminogen Activator in Rats

  1985cited by this paper
• Turnover of tissue plasminogen activator in normal and hepatectomized rabbits.

  1985cited by this paper
• Advances in Biotechnological Processes

  1984cited by this paper
• Tissue Plasminogen Activator: Chemical and Physiological Aspects

  1984cited by this paper
• Cloning and expression of human tissue-type plasminogen activator cDNA in E. coli

  1983cited by this paper
• In vivo and in vitro uptake and degradation of acetylated low density lipoprotein by rat liver endothelial, Kupffer, and parenchymal cells.

  1983cited by this paper
• Purification and identification of two structural variants of porcine tissue plasminogen activator by affinity adsorption on fibrin.

  1982cited by this paper
• Kinetics of the activation of plasminogen by human tissue plasminogen activator. Role of fibrin.

  1982cited by this paper
• Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture.

  1981cited by this paper
• Turnover of Human Extrinsic (Tissue-Type) Plasminogen Activator in Rabbits

  1981cited by this paper
• Purification and partial characterization of plasminogen activator from human uterine tissue.

  1979cited by this paper
• Preparation of isolated rat liver cells.

  1976cited by this paper

• Tissue Plasminogen Activator as an Approved Strategy for Ischemic Stroke: A Review of tPA’s Structure, Mechanism of Action and the Novel Targeting Methods

  2025cites this paper
• Post-Translational Oxidative Modifications of Hemostasis Proteins: Structure, Function, and Regulation

  2024cites this paper
• Antioxidant role of methionine-containing intra- and extracellular proteins

  2023cites this paper
• Reteplase Fc-fusions produced in N. benthamiana are able to dissolve blood clots ex vivo

  2021cites this paper
• Roles of the tissue-type plasminogen activator in immune response

  2021cites this paper
• Development and Testing of Thrombolytics in Stroke

  2021cites this paper
• Reteplase: Structure, Function, and Production

  2019cites this paper
• Interaction Between Heat Shock Proteins and Components of the Plasminogen Activator System in the Central Nervous System

  2019cites this paper
• Structures and Functions of Snake Venom Metalloproteinases (SVMP) from Protobothrops venom Collected in Japan

  2017cites this paper
• Fibrinolysis in Living Donor Liver Transplantation Recipients Evaluated Using Thromboelastometry: Impact on Mortality.

  2017cites this paper
• Effect of amino acids near the RGD sequence on binding activities between αIIbβ3 integrin and fibrinogen in the presence of RGD-containing synthetic peptides from elegantin and angustatin.

  2017cites this paper
• Scale up and pharmacokinetic study of a novel mutated chimeric tissue plasminogen activator (mt-PA) in rats

  2017cites this paper
• Can the benefits of rtPA treatment for stroke be improved?

  2017cites this paper
• Hepatocyte growth factor and alternative splice variants - expression, regulation and implications in osteogenesis and bone health and repair

  2016cites this paper
• Impacts of tissue-type plasminogen activator (tPA) on neuronal survival

  2015cites this paper
• Optimization of the Expression of Reteplase in Escherichia coli TOP10 Using Arabinose Promoter

  2015cites this paper
• Understanding the Functions of Endogenous and Exogenous Tissue-Type Plasminogen Activator During Stroke

  2015cites this paper
• Expression of the recombinant plasminogen activator (reteplase) by a non-lytic insect cell expression system

  2013cites this paper
• Serine‐proteases as plasminogen activators in terms of fibrinolysis

  2012cites this paper
• Expression of a Novel Chimeric Truncated t-PA in CHO Cells Based on in Silico Experiments

  2010cites this paper
• Characterization of the Hepatic Disposition of Lanoteplase, a Rationally Designed Variant of Tissue Plasminogen Activator in Rodents

  2007cites this paper
• variant of tissue plasminogen activator, in rodents

  2006cites this paper
• Pharmacology of thrombolytic agents

  2003cites this paper
• Directed evolution of proteins by exon shuffling

  2001cites this paper
• Hepatocyte growth factor/scatter factor‐induced intracellular signalling

  2000cites this paper
• Studies on the effect of fucosylated and non-fucosylated finger/growth-factor constructs on the clearance of tissue-type plasminogen activator mediated by the low-density-lipoprotein-receptor-related protein.

  1998cites this paper
• Regulation of tissue-type plasminogen activator concentrations by clearance via the mannose receptor and other receptors

  1997cites this paper
• Vascular smooth muscle cells potentiate plasmin generation by both urokinase and tissue plasminogen activator-dependent mechanisms: evidence for a specific tissue-type plasminogen activator receptor on these cells.

  1997cites this paper
• Spatial orientation of tissue-type plasminogen activator bound at the melanoma cell surface.

  1997cites this paper